\*\*\*Example Report\*\*\*

**ARUP** Laboratories

500 Chipeta Way – Salt Lake City, UT 84108 (800)522-2787 - www.aruplab.com Julio C. Delgado, M.D. M.S., Director of Laboratories Patient Age/Gender: Unknown Male Printed: 26-Dec-18 13:51:27

Procedure CCND1 FISH Result	<u>Result</u> Negative f	<u>Units</u>	Ref Interval	Accession Collected Received Verified 18-360-900048 26-Dec-18 26-Dec-18 26-Dec-18 26-Dec-18 13:40:00 13:48:38
CCND1 FISH Reference Number	S18-123			18-360-900048 26-Dec-18 26-Dec-18 26-Dec-18 13:40:00 13:40:00 13:48:38
CCND1 FISH Source	Tissue			18-360-900048 26-Dec-18 26-Dec-18 26-Dec-18 13:40:00 13:40:00 13:48:38
Total Cell Count	100			18-360-900048 26-Dec-18 26-Dec-18 26-Dec-18 13:40:00 13:40:00 13:48:38
Scoring Method	Manual			18-360-900048 26-Dec-18 26-Dec-18 26-Dec-18 13:40:00 13:40:0 13:48:38

26-Dec-18 13:40:00 CCND1 FISH Result:

Controls were run and performed as expected. This result has been reviewed and approved by Timothy Hanley, M.D., PhD.

26-Dec-18 13:40:00 CCND1 FISH Result: METHODOLOGY AND TEST INFORMATION:

IGH-CCND1 fluorescent in situ hybridization (FISH) analysis is designed to detect the IGH-CCND1 fusion associated with t(11;14)(q13;q32). Differentially labelled fluorescent probes directed against IGH and CCND1 were used (Abbott Molecular).

Fused signals within a cell are considered abnormal signal patterns and are consistent with IGH-CCND1 fusion. If a sample contains single fused signals seen in 17 percent or more of the cells, or two or more fused signals in 6 percent or more of the cells evaluated, it is considered a positive result.

IGH-CCND1 fusion is primarily found in mantle cell lymphoma, but this fusion is also found in other B-cell lymphoproliferative disorders including plasma cell neoplasms. Results should be correlated with clinical, morphologic and immunophenotypic data.

Fluorescence in situ hybridization (FISH) analysis was performed on a section from a paraffin-embedded tissue block. The area(s) for analysis were selected by histopathologic review of a matching hematoxylin and eosin stained section.

\* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab

Chart ID: 13159248 Page 1 of 2

\*\*\*Example Report\*\*\*

**ARUP** Laboratories 500 Chipeta Way – Salt Lake City, UT 84108 (800)522-2787 - www.aruplab.com Julio C. Delgado, M.D. M.S., Director of Laboratories

Patient Age/Gender: Unknown Male Printed: 26-Dec-18 13:51:27

Controls performed appropriately.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement A: aruplab.com/CS.

 $\textbf{*} \ \, \textbf{Abnormal}, \textbf{\#} = \textbf{Corrected}, \ \, \textbf{C} = \textbf{Critical}, \ \, \textbf{f} = \textbf{Footnote}, \ \, \textbf{H} = \textbf{High}, \ \, \textbf{L} = \textbf{Low}, \ \, \textbf{t} = \textbf{Interpretive Text}, \ \, \textbf{@} = \textbf{Reference Lab}$ 

Chart ID: 13159248 Page 2 of 2